{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:05:38Z","timestamp":1786133138304,"version":"build-2736575974"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract.<\/jats:title>\n                    <jats:p>\n                      It is unknown whether the addition of mycophenolate mofetil (MMF) to cyclosporine (CsA) and prednisone after renal transplantation (RTx) allows for a reduced dose of CsA, to minimize the incidence of CsA-related side effects and to reduce costs. Therefore, 313 renal allograft recipients were randomized for treatment with MMF (1000 mg twice a day), prednisone, and either conventional- or low-dose CsA during the first 3 mo after RTx. The target trough levels were 300 and 150 ng\/ml, respectively, during the first 3 mo and 150 ng\/ml in both groups thereafter. A total of 313 patients were included: 161 patients received a conventional dose and 152 received a low dose of CsA. During the first 6 mo after RTx, graft failure or patient death occurred in 19 of 161 patients (12%) in the conventional-dose group and in 11 of 152 patients (7%) in the low-dose group (not significant). Biopsy-proven acute rejection occurred in 36 of 161 patients (22%) in the conventional-dose group and in 29 of 152 patients (19%) in the low-dose group (not significant). The incidence of delayed graft function was similar in both groups (31 of 161 [19%]\n                      <jats:italic toggle=\"yes\">versus<\/jats:italic>\n                      28 of 152 [18%]; not significant). Serum creatinine did not differ between the conventional- and the low-dose groups: 151 \u00b1 56 \u03bcmol\/L\n                      <jats:italic toggle=\"yes\">versus<\/jats:italic>\n                      142 \u00b1 49 \u03bcmol\/L at 3 mo and 141 \u00b1 60 \u03bcmol\/L\n                      <jats:italic toggle=\"yes\">versus<\/jats:italic>\n                      136 \u00b1 49 \u03bcmol\/L at 6 mo. There were no differences between the groups regarding BP, lipid metabolism, and infectious complications. In the low-dose group, an estimated $500 per patient was saved on the costs of CsA. In conclusion, the addition of MMF to CsA and prednisone after RTx allows the use of a lower-than-conventional dose of CsA, without increasing the risk of rejection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.v1281750","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T20:53:24Z","timestamp":1619470404000},"page":"1750-1757","source":"Crossref","is-referenced-by-count":21,"title":["A Controlled Trial Comparing Two Doses of Cyclosporine in Conjunction with Mycophenolate Mofetil and Corticosteroids"],"prefix":"10.1681","volume":"12","author":[{"given":"RUUD G. L. DE","family":"S\u00c9VAUX","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PETER J. H. SMAK","family":"GREGOOR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RONALD J.","family":"HEN\u00c9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDRIES J.","family":"HOITSMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PIETER","family":"VOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WILLEM","family":"WEIMAR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TEUN VAN","family":"GELDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LUKAS B.","family":"HILBRANDS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-200108000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:29:14Z","timestamp":1786130954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-200108000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":0,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.v1281750","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}